Ascendis Pharma (ASND) PT Raised to $156 at TD Cowen
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $252.02 +1.87%
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 26
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 26
Join SI Premium – FREE
TD Cowen analyst Yaron Werber raised the price target on Ascendis Pharma (NASDAQ: ASND) to $156.00 (from $133.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
- Duos Technologies Group (DUOT) PT Raised to $27 at Cantor Fitzgerald on 'Extremely Attractive' Risk/Reward
- Ascendis Pharma (ASND) PT Raised to $360 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
